



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/663,894	09/16/2003	Chi-Ming Che	9661-041-999	4526
32172	7590	11/29/2006	EXAMINER	
DICKSTEIN SHAPIRO LLP 1177 AVENUE OF THE AMERICAS (6TH AVENUE) NEW YORK, NY 10036-2714				GEMBEH, SHIRLEY V
ART UNIT		PAPER NUMBER		
1614				

DATE MAILED: 11/29/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)
	10/663,894	CHE, CHI-MING
	Examiner Shirley V. Gembeh	Art Unit 1614

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 7/9/2006.
- 2a) This action is FINAL. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 1-4,6,7,9-11,13,25-28,30,31,33-35,37,55,58 and 59 is/are pending in the application.
- 4a) Of the above claim(s) 14-24,38-54, 56-57 and 60-63 is/are withdrawn from consideration.
- 5) Claim(s) _____ is/are allowed.
- 6) Claim(s) 1-4, 6-7, 9-11, 13 25-28, 30-31, 33-35,37, 55 and 58-59 is/are rejected.
- 7) Claim(s) _____ is/are objected to.
- 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) Notice of References Cited (PTO-892)
- 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date _____.
- 4) Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____.
- 5) Notice of Informal Patent Application (PTO-152)
- 6) Other: _____.

DETAILED ACTION

The response filed September 7, 2006 presents remarks and arguments to the office action mailed June 7, 2006. Applicants' arguments, filed, have been fully considered but they are not deemed to be persuasive. Rejections and/or objections not reiterated from previous office actions are hereby withdrawn. The following rejections and/or objections are either reiterated or newly applied. They constitute the complete set presently being applied to the instant application.

Status of claims

Claims 1-4, 6-7, 9-11, 13, 25-28, 30, 31, 33-35, 37, 55, 58 and 59 are pending.

Claims 14-24, 38-54, 56-57 and 60-63 are withdrawn.

Claims 1, 25, 55, and 58 are amended.

Claims 5, 8, 12, 29, 32, and 36 are cancelled.

Maintained Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:


(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claim 1-4, 6-7, 9-11, 13, 25-28, 30-31, 33-35, 37, 55 and 58-59 are rejected under 35 U.S.C. 103(a) as being unpatentable over Wheelhouse et al. US 6,087,493 in view of Argyris et al. J. biological chem.

Art Unit: 1614

Applicant traverses that (i) Wheehouse teaches or discloses cationic porphyrins that inhibit telomerase activities and does not disclose a method that directly induces apoptosis in cancer cells (see page 20 of remarks) (ii) that the reference does not teach inhibition of reverse transcriptase of human immunodeficiency virus type 1 (HIV-1).

In response, (i) Wheehouse teaches both cationic and negatively charged substituents



(see cols. 53 and 54, lines 45+) R is

As to the reference, not

disclosing apoptosis is traversed, because (see col. 2, lines 10-25), it clearly teaches

The telomeres are multiple tandem repeats of a highly conserved DNA sequence (in mammals 5'-TTAGGG-3') (SEQ ID NO:3) found at the ends of chromosomes and in human germline cells the telomeres may be 15-25 kilobases

10 long. The telomeres are dynamic structures responsible for chromosome stability and have a role in control of chromosome separation and are thus involved in regulation of the cell cycle. The end replication problem means that with each cell division about 60-100 bases are lost from the ends of the chromosomes and as the telomeres shorten, cells eventually
15 reach crisis and apoptosis is triggered. In immortal cell lines (tumors, germline and stem cells), an unusual enzyme activity—telomere terminal transferase, telomerase—is active which maintains the telomere length just above the
20 crisis level. Whether telomerase activation is a cause or effect of the neoplastic state remains a matter of debate. However, the observation that telomerase is active in almost all tumor cells but not in most normal tissues does mean that
25 telomerase presents a potentially highly selective target for the design of new agents to interfere with the growth of tumor cells.

how apoptosis is arrived at

Accordingly, the snagged information teaches in short that cells with long telomeres showed an incremental decrease in replicative capacity, whereas cells with short telomeres demonstrated apoptosis.

As to (ii), all the claim limitation does not have to be met by one reference, as this is a 103 type rejection, it gives one of skill to combine teachings or disclosure at the time the claimed invention was made to be able to make and use the claim invention. Thus the reason why another reference was used to show obviousness.

Next, Applicant argues that among the metals tested AuIII exhibited only 23% telomerase inhibition compared to the others H₂ or ZnII. (see page 21 of remarks).

In response, inhibition is inhibition, the claims do not indicate at what extent inhibition is carried out, if Applicants' argument is what percentage of inhibition is seen when the claimed invention is used then it need to be as part of the claim invention. Applicants remarks (see page 322) states that stabilization of gold (III) or AU(III) and no acute cytotoxicity is found is also disclosed in the teaching of Wheehouse (see col. 16, lines 45-65). As to intercalation, (see remarks page 22, para. 1), the reference clearly teaches that compounds of such are known to intercalate with DNA (see col. 17, lines 38+).

With regards to the argument (see page 23, para.3, that Argyris does not disclose Au(III) and combination of both references does not render the claim invention obvious.

In response, Argyris, does not have to teach (Au(III)), the Wheelhouse reference teaches the different metal ions that are capable of such a function (see col. 3, lines 15+) one skilled in the art would have been motivated to substitute Zn for Au and would have expected a successful result in doing so.

Applicant's arguments filed have been fully considered but they are not persuasive. (See above reasons).

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

No claim is allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Shirley V. Gembeh whose telephone number is 571-272-8504. The examiner can normally be reached on 8:30 -5:00, Monday- Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ardin Marschel can be reached on 571-272-0718. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

SVG
11/21/06

Ardin H. Marschel 11/27/06
ARDIN H. MARSCHEL
SUPERVISORY PATENT EXAMINER